Pfizer shares are trading at a one-month low, down 2.8% from mid-September. Since the beginning of the year, the emitter’s quotes dropped by more than 17.5%. Pfizer announced the merger of its generic drug business segment with Mylan, which will be part of the upcoming M&A deal. Earlier, the company published promising test results for a new drug in the treatment of eczema.
During the previous week, Pfizer shares dropped by 0.86%. S&P500 index went down by 0.51% during the same period.
If the price consolidates below the support level of 35.50, #PFE quotes are expected to decline further. Potential profits should be locked in by orders at 34.50, 33.50, and 33.00. Stop loss – 36.50.
If the price consolidates above 37.00, one may consider buying the company’s stock. The moving potential is aimed at the area of 38.50–39.50. Stop loss – 36.00.
Implementation period: 3 days.
34.50, 33.50, 33.00
34.10, 35.50, 37.00, 37.75, 38.75
34.10, 35.50, 37.00, 37.75, 38.75
Support and resistance
The emitter has stabilized after a sharp fall since mid-July. At the moment, the company’s shares are consolidating. Local support and resistance levels are at 35.50 and 37.00, respectively. The instrument has the potential to further decline.
Indicators don’t give a clear signal: the price crossed MA(50); MACD histogram is located near the zero line. Positions are to be opened from key levels.
Comparing the company’s multiplier with its competitors in the industry, we can say that #PFE shares are neutral.
Support levels: 35.50, 34.10.
Resistance levels: 37.00, 37.75, 38.75.
Pfizer Inc. develops, manufactures and sells. health care products worldwide. It provides medicines and vaccines available in various therapeutic areas, including inner medicine, vaccines, oncology, inflammation and immunology, and rare diseases under Lyrica, Chantix / Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel , Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF / Xyntha brands. The company provides consumer health care products that include over-the-counter medicines, including dietary supplement products called Centrum, Caltrate and Emergen-C; pain management products under Advil and ThermaCare names; gastrointestinal products under Controlled Nexium and Neonium 24HR / Nexium names; and respiratory and personal care products under the names Robitussin, Advil Cold & Sinus, and ChapStick. In addition, it provides products that lose marketing patent protection or lost it; branded kinds products; sterile generic injection products; biosimilars; and anti-infections under the Lipitor, Premarin people, Norvasc, Lyrica, Celebrex, Viagra, Inflectra / Remsima, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim and Retacrit, Ixifi Infliximab BS names. Moreover, the company is also involved in the contract manufacturing business. It caters for wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual supply offices, as well as disease control and prevention centers. The company has co-operation and / or co-promotion agreements with Bristol-Myers Squibb Company, Astellas US Pharma, Inc., and Oncolytics Biotech Inc.; licensing agreement with BionTech AG; strategic alliance with Verily Life Sciences LLC; and cooperation agreements with Pfizer, Merck & Co., Inc., and Lilly Eli & Company, as well as KGaA Merck, Nektar Therapeutics, and Syapse, Inc. Pfizer Inc. was founded. in 1849 and has its headquarters in New York, New York.
Jason P. Vasser gives us an analysis into the recent geo-political news hitting the services, legal, and technology sectors. He has been an financial advisor for over 10 years in the NYC and in recently turned his experience investment and passion for journalism into a full time role. His responsibility is for the analysis of companies and writing valuable information for shareholder community.
Jason is an a seasoned writer who has a passion for tech and travel. His goal is to see travel the world and report on the use of technology from a market perspective.